Search clinical trials for: Mirapex (pramipexole)

Total 213 results

Boehringer Ingelheim

Completed

Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)

Restless Legs Syndrome
Boehringer Ingelheim

Completed

The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa

Parkinson Disease

China
Massachusetts General Hospital
National Institute of Mental Health (NIMH)

Completed

Effectiveness of Pramipexole for Treatment-Resistant Depression

Depression

United States
Teva Pharmaceuticals USA

Completed

Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions

Healthy

United States
Northwell Health
Stanley Medical Research Institute

Completed

Cognitive Enhancement in Bipolar Disorder

Bipolar Disorder

United States
University of California, San Diego
National Institute of Mental Health (NIMH); New York State Psychiatric Institute

Not yet recruiting

Pramipexole to Enhance Social Connections

Depression | Anxiety Disorders | Anxiety | Social Disconnection

United States
Teva Pharmaceuticals USA

Completed

Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions

Healthy

United States
Institute for Neurodegenerative Disorders
United States Department of Defense; Boehringer Ingelheim

Completed

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease

Parkinson Disease | Parkinsonian Syndrome

United States
Boehringer Ingelheim

Completed

Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease

Parkinson Disease

Japan
Boehringer Ingelheim

Completed

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

Parkinson Disease

United States
Seoul National University Hospital

Unknown

Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)

Parkinson's Disease

Korea, Republic of
Boehringer Ingelheim

Completed

Pivotal Study in Advanced Parkinsons Disease Patients

Parkinson Disease

Austria, Czech Republic, Hungary, India, Italy, Korea, Republic of, Philippines, Poland, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease

Parkinson Disease
Brigham and Women's Hospital
National Institute of Mental Health (NIMH); Northwell Health; Icahn School of... and other collaborators

Completed

Targeting Cognition in Bipolar Disorder With Pramipexole (PRAM-BD)

Bipolar Disorder

United States
New York State Psychiatric Institute
National Institute of Mental Health (NIMH); Columbia University; Icahn School... and other collaborators

Completed

Imaging Dopamine Release in Depression

Major Depressive Disorder

United States
University of Pecs

Withdrawn

Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor

Essential Tremor

Hungary
Neuropsychiatric Research Institute, Fargo, North...

Withdrawn

Pramipexole for Binge Eating Disorder

Binge Eating Disorder
Dr. D McIntosh & Dr. K Kjernisted Clinical Research...
AstraZeneca

Completed

Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

Bipolar Depression

United States, Canada
Boehringer Ingelheim

Completed

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

Early Parkinson Disease (Early PD)

United States, Argentina, Austria, Czech Republic, Finland, Germany, Hungary, India, Japan, Malaysia, Russian Federation, Slovakia, Taiwan, Ukraine
Boehringer Ingelheim

Completed

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Healthy
Massachusetts General Hospital

Recruiting

Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD

Sleep Disorder | Restless Legs Syndrome | Opioid-use Disorder | Opioid Withdrawal

United States
Boehringer Ingelheim

Completed

In Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets Pramipexole in Healthy Male Volunteers

Healthy
Rajesh Pahwa, MD
GlaxoSmithKline

Completed

Pramipexole Conversion to Ropinirole Controlled Release (CR)

Parkinson Disease

United States
Boehringer Ingelheim

Terminated

Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome

Tourette Syndrome

United States, Germany
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients (RLS)

Idiopathic Restless Legs Syndrome

United States, Spain, Finland, Italy, Germany, Sweden, Austria, Netherlands, United Kingdom
Baylor College of Medicine
National Institute on Drug Abuse (NIDA)

Completed

Pramipexole as a Treatment for Cocaine Dependence

Substance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine Addiction

United States
Boehringer Ingelheim

Completed

Bioavailability of Increasing Pramipexole Doses of Oral Extended Release (ER) Tablets in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers

Healthy

China
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance

Restless Legs Syndrome

United States
Boehringer Ingelheim

Completed

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

Parkinson Disease

Japan
Boehringer Ingelheim

Completed

A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS.

Idiopathic Restless Legs Syndrome

Japan
Boehringer Ingelheim

Completed

The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia

Heart Failure
Dexa Medica Group

Completed

Bioequivalence Study of Two Formulations of Pramipexole Tablets 0.25 mg

Healthy

Indonesia
First Affiliated Hospital of Zhejiang University
Hongguan biological pharmaceutical co.

Terminated

Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets (PLKS-BE)

Parkinson's Disease

China
Boehringer Ingelheim

Completed

Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome

Restless Legs Syndrome

Japan
Pfizer

Completed

Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex) (POINT X)

Dupuytren's Contracture

United Kingdom, Sweden, Spain, Germany, Hungary, France, Denmark, Italy
Jeppe Lange, MD

Completed

Injectable Collagenase and Percutaneous Needle Fasciotomy for Dupuytren's Contracture

Dupuytrens Contracture

Denmark
Boehringer Ingelheim

Completed

Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease

Parkinson Disease

France, Germany, Netherlands
Endo Pharmaceuticals

Completed

Post Approval Commitment Study

Dupuytren's Contracture

Norway, Spain
Jeppe Lange

Completed

Collagenase is a Common Treatment of MCP and PIP Joint Contractures in Dupuytrens Disease

Dupuytren Contracture
Boehringer Ingelheim

Completed

Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients

Parkinson Disease

China
Boehringer Ingelheim

Completed

Long-term Administration Study of SND 919 Tablets in Parkinson's Disease

Parkinson Disease
Teva Neuroscience, Inc.

Completed

A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease

Parkinson's Disease
Sandoz

Completed

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

Parkinson's Disease

Korea, Republic of
Boehringer Ingelheim

Completed

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

Parkinson Disease

United States, Austria, Finland, France, Germany, Italy, Japan, Spain, Sweden, United Kingdom
Boehringer Ingelheim

Completed

Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances

Depression | Restless Legs Syndrome

Finland, France, Germany, Ireland, Italy, Korea, Republic of, Spain, Sweden, United Kingdom
Augusta University
GlaxoSmithKline

Completed

SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole

Restless Legs Syndrome

United States
Mansoura University

Enrolling by invitation

Clinical and Radiographic Evaluation of Photodynamic Therapy for Root Canal Treatment of Primary Molars

Photodynamic Therapy

Egypt
Boehringer Ingelheim

Completed

a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients

Parkinson Disease

China

Search clinical trials for: Mirapex (pramipexole)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations